Research location
Wilrijk
Belgium
Advertisement
Research activity in Wilrijk
BelgiumCureCurrent currently publishes aggregate city-level research activity for this location: 178 trials and 178 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Wilrijk
178 linked trials · page 3 of 4Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisNCT01201356 · 2010-09-13 · 1 site observation
COMPLETED
A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid ArthritisNCT01921478 · 2010-08-01 · 1 site observation
COMPLETED
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)NCT01199861 · 2010-08-01 · 1 site observation
COMPLETED
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)NCT01120184 · 2010-07-31 · 1 site observation
COMPLETED
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)NCT01077154 · 2010-06-02 · 1 site observation
TERMINATED
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast CancerNCT01132664 · 2010-05-01 · 1 site observation
TERMINATED
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) PatientsNCT01127750 · 2010-05-01 · 1 site observation
COMPLETED
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast CancerNCT01038804 · 2009-12-01 · 1 site observation
COMPLETED
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast CancerNCT00876395 · 2009-09-10 · 1 site observation
COMPLETED
A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate CancerNCT00992186 · 2009-09-01 · 1 site observation
COMPLETED
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast CancerNCT00880009 · 2009-07-30 · 1 site observation
TERMINATED
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or AnastrozoleNCT00863655 · 2009-06-03 · 1 site observation
COMPLETED
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast CancerNCT00807859 · 2009-03-09 · 1 site observation
COMPLETED
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid TumorsNCT00841191 · 2009-03-01 · 1 site observation
COMPLETED
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast CancerNCT00793546 · 2009-02-01 · 1 site observation
TERMINATED
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to LevodopaNCT00627640 · 2009-02-01 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast CancerNCT00802945 · 2008-10-01 · 1 site observation
COMPLETED
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the ElectrocardiogramNCT00786838 · 2008-10-01 · 1 site observation
COMPLETED
Faslodex Registry: Fulvestrant in Current Clinical PracticeNCT00735215 · 2008-10-01 · 1 site observation
COMPLETED
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel ChemotherapyNCT00676650 · 2008-07-01 · 1 site observation
TERMINATED
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast CancerNCT00706030 · 2008-04-29 · 1 site observation
COMPLETED
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabNCT00625898 · 2008-04-01 · 1 site observation
TERMINATED
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung CancerNCT01161173 · 2008-04-01 · 1 site observation
COMPLETED
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)NCT00623103 · 2008-01-01 · 1 site observation
COMPLETED
Methotrexate-Inadequate Response StudyNCT00559585 · 2008-01-01 · 1 site observation
COMPLETED
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast CancerNCT00528567 · 2007-12-01 · 1 site observation
COMPLETED
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast CancerNCT00558103 · 2007-12-01 · 1 site observation
COMPLETED
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast CancerNCT00445458 · 2007-09-11 · 1 site observation
COMPLETED
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With HerceptinNCT01152606 · 2007-08-30 · 1 site observation
COMPLETED
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.NCT00428220 · 2007-07-01 · 1 site observation
COMPLETED
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer PatientsNCT00511459 · 2007-07-01 · 1 site observation
COMPLETED
Tysabri Observational ProgramNCT00493298 · 2007-06-29 · 1 site observation
COMPLETED
Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the BreastNCT00470236 · 2007-06-01 · 1 site observation
UNKNOWN
Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast CancerNCT00463788 · 2007-06-01 · 1 site observation
COMPLETED
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DNCT00490139 · 2007-05-16 · 1 site observation
COMPLETED
An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate CancerNCT00537381 · 2007-05-01 · 1 site observation
COMPLETED
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast CancerNCT00372996 · 2007-02-01 · 1 site observation
TERMINATED
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD PatientsNCT00332917 · 2007-02-01 · 1 site observation
COMPLETED
Effectiveness of Anti-Psychotic in GPs SettingNCT00543088 · 2007-01-01 · 1 site observation
COMPLETED
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 PositiveNCT00372424 · 2006-12-01 · 1 site observation
COMPLETED
An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast CancerNCT00425854 · 2006-11-01 · 1 site observation
COMPLETED
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)NCT00385827 · 2006-11-01 · 1 site observation
TERMINATED
TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in BelgiumNCT00886288 · 2006-09-01 · 1 site observation
COMPLETED
Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast CancerNCT00300781 · 2006-08-04 · 1 site observation
COMPLETED
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast CancerNCT00338247 · 2006-07-01 · 1 site observation
APPROVED_FOR_MARKETING
SLV308 for Treatment of Patients With Early Parkinson's DiseaseNCT00269516 · 2006-06-01 · 1 site observation
COMPLETED
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mgNCT00313170 · 2006-05-30 · 1 site observation
COMPLETED
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast CancerNCT00333775 · 2006-03-01 · 1 site observation
COMPLETED
Observational Study of Pergolide Mesylate and Cardiac ValvulopathyNCT00311532 · 2006-03-01 · 1 site observation
COMPLETED
Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast CancerNCT00243503 · 2006-02-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.